Selected article for: "antiviral efficacy and coronavirus SARS"
Author: Chang Chen; Jianying Huang; Zhenshun Cheng; Jianyuan Wu; Song Chen; Yongxi Zhang; Bo Chen; Mengxin Lu; Yongwen Luo; Jingyi Zhang; Ping Yin; Xinghuan Wang
Title: Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
  • Document date: 2020_3_20
    • ID: 14he8n3u_1
    Snippet: The epidemic coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 started in Dec. 2019. As of Apr. 8, 2020, the WHO reported 1,452,178 confirmed cases across more than 130 countries with a global mortality rate of 5.8%. 1, 2 At the moment, no specific treatment exists for COVID-19. Standard practice of care focus on treating the clinical symptoms (pyrexia, cough, and acute respiratory distress syndromes (ARDS)) of patients with supportive car.....
    Document: The epidemic coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 started in Dec. 2019. As of Apr. 8, 2020, the WHO reported 1,452,178 confirmed cases across more than 130 countries with a global mortality rate of 5.8%. 1, 2 At the moment, no specific treatment exists for COVID-19. Standard practice of care focus on treating the clinical symptoms (pyrexia, cough, and acute respiratory distress syndromes (ARDS)) of patients with supportive care such as fluid management and auxiliary oxygen therapy. No proven clinical efficacy of antiviral agent for COVID-19

    Search related documents:
    Co phrase search for related documents
    • acute respiratory cough and ARDS distress syndrome acute respiratory cough: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute respiratory cough and clinical symptom: 1
    • acute respiratory cough and distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory cough and mortality rate: 1, 2, 3, 4, 5, 6
    • acute respiratory cough and oxygen therapy: 1
    • acute respiratory cough and SARS cause: 1, 2, 3
    • acute respiratory cough and specific treatment: 1
    • antiviral agent and ARDS distress syndrome: 1, 2, 3, 4, 5
    • antiviral agent and clinical efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • antiviral agent and clinical symptom: 1
    • antiviral agent and distress syndrome: 1, 2, 3, 4, 5, 6, 7
    • antiviral agent and global mortality rate: 1
    • antiviral agent and mortality rate: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral agent and oxygen therapy: 1
    • antiviral agent and SARS cause: 1, 2, 3, 4, 5
    • antiviral agent and specific treatment: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral agent clinical efficacy and clinical efficacy: 1
    • antiviral agent clinical efficacy and clinical symptom: 1
    • ARDS distress syndrome and specific treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25